

**BEST AVAILABLE COPY****Docket No.: 1408.017**Substitute Listing of Claims

This listing of claims will replace all prior versions and listings of claims in the application.

1. **(Currently Amended)** A composition for use in manufacturing an adhesive layer for transdermal preparation, said composition comprising ~~a non-aqueous~~ an organic solvent, a drug to be delivered through skin and an acrylic ~~adhesive polymer~~, and said composition forming one phase, wherein the drug is hydrophilic or in a salt form and the acrylic ~~polymer adhesive~~ has an acrylic backbone and a poly (ethylene oxide) or poly (ethylene oxide) monomethyl ether side chain.

2. **(Previously Presented)** The composition according to claim 1, further comprising at least one additional component chosen from a solubilizer and a skin permeation enhancer.

3. **(Previously Presented)** The composition according to claim 1, wherein the amount of drug in the preparation is in a range of 1-50% by weight, based on the total weight of the adhesive layer.

4. **(Previously Presented)** The composition according to claim 1, wherein the molecular weight of the poly (ethylene oxide) or poly(ethylene oxide) monomethyl ether is in a range of 100-30000, and wherein the amount of poly(ethylene oxide) or poly(ethylene oxide) monomethyl ether in the acrylic polymer is in the range of 0.01-50% by weight based on the total weight of the acrylic polymer.

5. **(Previously Presented)** The composition according to claim 4, wherein the molecular weight of the poly(ethylene oxide) or poly(ethylene oxide) monomethyl ether is in a range of 400-5000, and wherein the amount of poly(ethylene oxide) or poly(ethylene oxide) monomethyl ether in the acrylic polymer is in a range of 0.05-30 % by weight based on the total weight of the acrylic polymer.

**Docket No.: 1408.017**

6. **(Previously Presented)** The composition according to claim 1, wherein the drug is selected from a group consisting of sodium, potassium and diethylammonium salts of diclofenac, amfenac, aceclofenac and aleclofenac; ketorolac tromethamine; hydrochloride, phosphate and methanesulfonate salts of eperisone and tolperisone; oxybutynin chloride; hydrochloride, hydrobromide, fumarate, succinate and tartrate salts of diphenhydramine, ketotifen, doxylamine, promethazine and trimeprazine; hydrochloride and sulfate salts of tulobuterol, clenbuterol, procaterol and terbutaline; acetate, succinate, valerate and disodium phosphate salts of hydrocortisone, dexamethasone and betamethasone; and hydrochloride salts of ondansetron, granisetron and ramosetron.

7. **(Previously Presented)** The composition according to claim 2, wherein the solubilizer comprises at least one component selected from a group consisting of ethanol, isopropanol, poly(ethylene glycol), ethoxydiglycol, propylene glycol, glycerin and dimethylsulfoxide, and wherein the amount of solubilizer in the adhesive layer is in a range of 0.5-50% by weight based on the total weight of the adhesive layer.

8. **(Previously Presented)** The composition according to claim 2, wherein the skin permeation enhancer comprises at least one component selected from a group consisting of higher fatty acids; higher alcohols; higher fatty acid esters; fatty acid esters; fatty acid ethers of poly(ethylene glycol); fatty acid esters of poly(ethylene glycol); fatty acid ethers of propylene glycol; fatty acid esters of propylene glycol; sorbitan fatty acid esters; poly(ethylene glycol) sorbitan fatty acid esters; terpenes; sulfoxides; pyrrolidones; amides; and *N*-hydroxy methyl lactate, sorbitol, urea, squalene, olive oil, mineral oil and its derivative, and wherein the amount of skin permeation enhancer in the adhesive layer is in a range of 0.5-50% by weight based on the total weight of the adhesive layer.

9. **(Previously Presented)** The composition according to claim 8, wherein the skin permeation enhancer comprises at least one component selected from a group consisting of lauric acid, oleic acid, lauryl alcohol, oleyl alcohol, glycerol monolaurate, glycerol monooleate, polyoxyethylene(2) lauryl ether, polyoxyethylene(2) oleyl ether, propylene glycol monolaurate,

**Docket No.: 1408.017**

propylene glycol monooleate, sorbitan monolaurate, sorbitan monooleate, lauryl diethanolamide, *N*-methyl-2-pyrrolidone and isopropyl myristate.

10. ***(Previously Presented)*** The composition according to claim 7, wherein the amount of the solubilizer and of the skin permeation enhancer in the adhesive layer are each in a range of 1-30% by weight, based on the total weight of the adhesive layer.

11. ***(Previously Presented)*** The composition according to claim 2, wherein the amount of drug is in a range of 1-50% by weight, based on the total weight of the adhesive layer.

12. ***(Previously Presented)*** The composition according to claim 2, wherein the molecular weight of the poly(ethylene oxide) or poly(ethylene oxide) monomethyl ether is in a range of 100-30000, and the amount of poly(ethylene oxide) or poly(ethylene oxide) monomethyl ether is in the range of 0.01-50% by weight based on the total weight of the acrylic polymer.

13. ***(Previously Presented)*** The composition according to claim 2, wherein the drug is selected from a group consisting of sodium, potassium and diethylammonium salts of diclofenac, amfenac, aceclofenac and alclofenac; ketorolac tromethamine; hydrochloride, phosphate and methanesulfonate salts of eperisone and tolperisone; oxybutynin chloride; hydrochloride, hydrobromide, fumarate, succinate and tartrate salts of diphenhydramine, ketotifen, doxylamine, promethazine and trimeprazine; hydrochloride and sulfate salts of tulobuterol, clenbuterol, procaterol and terbutaline; acetate, succinate, valerate and disodium phosphate salts of hydrocortisone, dexamethasone and betamethasone; and hydrochloride salts of ondansetron, granisetron and ramosetron.

14. ***(Previously Presented)*** The composition according to claim 8, wherein the amount of the solubilizer and of the skin permeation enhancer in the adhesive layer are each in a range of 1-30% by weight, based on the total weight of the adhesive layer.

**Docket No.: 1408.017**

15. *(Previously Presented)* The composition according to claim 9, wherein the amount of the solubilizer and of the skin permeation enhancer in the adhesive layer are each in a range of 1-30% by weight, based on the total weight of the adhesive layer.

16-17. *(Canceled)*

18. *(Currently Amended)* A method for manufacturing a transdermal preparation, said method comprising

providing an adhesive composition comprising an acrylic adhesive dissolved in an organic solvent and forming one phase, the acrylic adhesive having a poly (ethylene oxide) or poly (ethylene oxide) monomethyl ether side chain;

~~combining a non-aqueous polymer solution with the adhesive composition with a drug to be delivered through skin, wherein the drug is hydrophilic or in a salt form and the non-aqueous polymer solution comprises a polymer having an acrylic backbone and a poly (ethylene oxide) or poly (ethylene oxide) monomethyl ether side chain; and~~

applying the resulting solution to a substrate to form a transdermal preparation having an adhesive layer comprising the drug and the polymer.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**